

6 November 2017

Ingrid Wei  
Market Surveillance Analyst  
National Stock Exchange of Australia (NSX)

Dear Ingrid

**Angy (China) Medical Limited (Angy) - Periodic Disclosure Query**

We refer to your letter dated 31 October 2017.

Angy provides the following responses to the items raised in paragraph 2 of your letter:

- (a) *Can the Company please provide information supporting the material change in its revenue?*

Angy provides the following information:

Due to the exhibition and promotion took place in Shanghai and Shenzhen during the first half year of 2016, it attracts new customers and leads an increase of sales order during the second half year of 2016. The number of customers increases from 517 as at 30 June 2016 to 685 up to now.

- (b) *When did the Company first become aware of the information regarding possible change in business activities that could result in material change in revenue?*

The increase in the revenue was set out in the half year preliminary report provided to NSX on 13 September 2017. Angy first became aware that there may be a material change in revenue when preparing its half year financial statements. Angy was only able to confirm that there would be a comparative increase in revenue and profit once those half year financial statements were finalised. Angy notes that the information in the 13 September 2017 report is consistent with the information in the half year report released on 20 October 2017.

- (a) The increase in revenue is as a result of an increased sales across multiple contracts entered into by Angy.
- (b) Management accounts were prepared annually in 2016. After the year 2016, those accounts would be prepared half yearly.
- (c) *Does the Company believe it is in compliance with Listing Rule 6.4 as the financial position of the group has significantly changed from the period ended 30 June 2016 to the period ended 30 June 2017 without any information being released to the market supporting the significant change in the financial position?*

Angy confirms that it is of the view that it has complied with its continuous disclosure obligations.

Angy released its preliminary final report for the year ended 31 December 2016 on 17 March 2017, and its annual report for the year ended 31 December 2016 on 31 March 2017. These

announcements provided the market with updated information on Angy's financial performance and position as at 31 December 2016.

The directors' report in the annual report set out further information regarding Angy's operations that was in addition to the information set out in its information memorandum dated 13 January 2017 (and released by NSX on 23 February 2017).

As part of its NSX listing, Angy implemented corporate governance structures and processes in relation to its continuous disclosure obligations, and to independently verify and safeguard the integrity of its financial reporting and obligations. Angy is of the view that its current structures and processes are sufficient, and will continue to assess these structures and processes as its operations evolve.

Please contact me if you have any further queries.

Yours sincerely

A handwritten signature in blue ink, appearing to be 'Cen Weiting', written over a horizontal line.

Cen Weiting  
Company Secretary  
Angy (China) Medical Limited